Clinical Trial Update: Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

View source ↗

Summary

Expanded Access program for AMTAGVI is out of specification for commercial release, triggering quality controls and potential safety concerns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Amtagvi (lifileucel)

Snippet

Sponsor: Iovance Biotherapeutics, Inc. | Conditions: Unresectable Melanoma, Metastatic Melanoma | Status: AVAILABLE